// App-Quantinova.ai

: A CD79b Targeting ADC with Superior Anti-Tumor Activity and Safety Resulting in Significantly Improved Therapeutic Index (TI): Safe and Efficacious CD79b ADC

Researchers

Presenter

  • Bernd Schlereth

Principal Investigators

  • Isabella Attinger-Toller

  • Philipp Probst

  • ROMAIN BERTRAND

  • Ramona Stark

  • Roger Santimaria

  • Emma Renard

  • Rachael Fay

  • Jeff P. Sharman

  • Dragan Grabulovski

  • Philipp Spycher

Medical Centers

  • Willamette Valley Cancer Institute and US Oncology Research, Eugene, OR

  • Araris Biotech AG, Au Zurich, Switzerland

Locations

  • United States

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Oncology (ONC)

Disease

  • Non-Hodgkin's Lymphoma

  • Solid malignancies

  • Non‐Hodgkin Lymphoma

  • Lymphomas

Biomarkers

  • Cartilage oligomeric matrix protein

  • Apparent diffusion coefficient

Drug/Treatment

  • monomethyl auristatin E

  • Polatuzumab vedotin

Outcome

  • N/A

Study Design

  • Efficacy

  • Safety

  • Pharmacokinetics

  • Active Comparator

  • Tolerability

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved